Uterine Cervical Neoplasms Clinical Trial
Official title:
BGOG-cx1/ENGOT-cx1: "Randomized Double-blind Phase II Study Comparing 3-weekly Carboplatin + Paclitaxel With or Without Concomitant and Maintenance Nintedanib (NINTEDANIB) in Advanced or Recurrent Cervical Carcinoma."
Indication: Treatment of subjects with advanced (FIGO stage IVB) or recurrent cervical cancer, prior radiochemotherapy or neo-adjuvant chemotherapy is allowed. Study design: This is a phase II randomized, double blind and placebo controlled trial evaluating the efficacy of Nintedanib/placebo in combination with the standard carboplatin and paclitaxel followed by Nintedanib/placebo maintenance in the treatment of patients with advanced or recurrent cervical cancer. A total of 120 patients will be randomized between the experimental and control arm in a 1:1 ratio. Randomization will be stratified for 1previous chemotherapy for metastatic disease (yes/no) and 2disease status (Stage IVB primary versus recurrent disease). Experimental arm: Subjects will receive 6 cycles of 3-weekly carboplatin (AUC 5) + paclitaxel (175 mg/m2) and Nintedanib 200 mg BID followed by Nintedanib maintenance until progression or for a total maximum duration of 120 weeks. Control arm: Subjects will receive 6 cycles of 3-weekly carboplatin (AUC 5) + paclitaxel (175 mg/m2) and placebo 200 mg BID followed by placebo maintenance until progression or for a total maximum duration of 120 weeks. Subjects without evidence of disease progression after completion or discontinuation of the study treatment will be followed until radiographic disease progression, withdrawal of consent or death.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT03225443 -
Observation and Evaluation of Short-term Curative Effect of Local Advanced Cervical Cancer Treated With Particle Radiotherapy Versus Neoadjuvant Chemotherapy
|
N/A | |
| Recruiting |
NCT01373723 -
Economic Evaluation of Three Populational Screening Strategies for Cervical Cancer
|
N/A | |
| Terminated |
NCT01234480 -
Intended Use Study of the BD SurePath Plus™ Pap
|
||
| Terminated |
NCT01194609 -
A Pilot Study of Radiation-Immune Cell Combination Therapy in Cervical Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT02808832 -
An HPV Vaccine Provider Intervention in Safety Net Clinics
|
N/A | |
| Completed |
NCT01014026 -
Self-sampling and Human Papillomavirus (HPV)-Testing for Unscreened Women in Cervical Cancer Prevention
|
Phase 3 | |
| Terminated |
NCT01075412 -
FLT PET Imaging for Cervical Cancer
|
Phase 2 | |
| Completed |
NCT02865889 -
Cost-Effectiveness and Patients Satisfaction of Conventional vs Robotic-Assisted Laparoscopy in Gynecologic Oncologic Indications
|
N/A | |
| Completed |
NCT00377845 -
Cervix Cytological Screening - Comparison of Tampon Self-Test and the Routine Smear.
|
Phase 0 | |
| Recruiting |
NCT05531981 -
Detection of Minimal Residual Disease Based on HPV ctDNA in Cervical Cancer
|
||
| Recruiting |
NCT05393440 -
First-in-human (FIH) Phase I Trial of BS-006 in Cervical Cancer
|
Phase 1 | |
| Recruiting |
NCT05007106 -
MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)
|
Phase 2 | |
| Completed |
NCT02866006 -
Safety and Tolerability Evaluation Study of BVAC-C in Patients With HPV Type 16 or 18 Positive Cervical Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT03270995 -
Cognitive-Existential Group Therapy to Reduce Fear of Cancer Recurrence: A RCT Study
|
N/A | |
| Completed |
NCT02320578 -
2D Versus 3D Radical Laparoscopic Hysterectomy for Cervical Cancer: a Prospective Randomized Trial
|
N/A | |
| Terminated |
NCT02900248 -
CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice
|
||
| Not yet recruiting |
NCT05065853 -
Urinary and Vaginal HPV Testing in Cervical Cancer Screening
|
||
| Completed |
NCT01231945 -
Low-Cost Molecular Cervical Cancer Screening Study
|
N/A | |
| Completed |
NCT01717391 -
[F-18] Fluorothymidine PET/CT Imaging for Pelvic Cancers
|
Phase 2 | |
| Active, not recruiting |
NCT04947605 -
Epidemiological Landscape of Cervical Cancer in Latin America
|